Cytarabine
Neoplastic Meningitis
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06230055CT.gov Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis | — | Recruiting | — | — | — |
NCT01645839CT.gov Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer | — | Completed | — | — | — |
NCT00992602CT.gov Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer | — | Completed | — | — | — |
NCT00964743CT.gov Depocyt® With Sorafenib in Neoplastic Meningitis | — | Terminated | — | — | — |
NCT00523939CT.gov DepoCyt for Active Lymphomatous or Leukemic Meningitis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplastic Meningitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | Fudan University | Approved | BBB · 72 |
| Methotrexate | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
| Dexasone | Shanghai Cancer Hospital, China | P2 | B |
| Lorlatinib | Guangdong Association of Clinical Trials | P4 | B |
| Durvalumab | Hui Bu | P4 | B |
| Etoposide | Guangzhou Medical University | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Guangzhou Medical University | P2 | B |
| Paclitaxel Trevatide | Angiochem Inc | P3 | B |
| Cyclophosphamide | Medical College of Wisconsin | P2 | B |
+39 more in the Neoplastic Meningitis cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cytarabine in Neoplastic Meningitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cytarabine-neoplastic-meningitis-65094
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →